Research site

Naples, Florida 34119

4 studies enrolling now · 37 studies all time

What they study most

ASCVD Management, Anemia in Chronic Kidney Disease Patients Not on Dialysis, Atherothrombosis, Bronchiectasis With Pseudomonas Aeruginosa Colonization, COPD, COPD (Chronic Obstructive Pulmonary Disease), Carcinoma, Cardiovascular Death, Cardiovascular Disease, Cerebral Stroke, Cerebrovascular Stroke, Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Studies at this site

• A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization — Recruiting now
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Recruiting now
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations — Completed
• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis — Stopped early
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. — Completed
• Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States — Completed
• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure — Completed
• A Multicenter Assessment of ALD403 in Frequent Episodic Migraine — Completed
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 — Stopped early
• Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis — Completed
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. — Completed
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States — Completed
• A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) — Stopped early
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
• Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain — Stopped early
• Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications — Completed
• Iressa Expanded Access Program (EAP) — Completed
• Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed
• Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients — Completed